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A Ab bs st tr ra ac ct t
P Pu ur rp po os se e: :   To compare the presentation of invasive breast cancer in BRCA1 and BRCA2 mutation carriers
with and without prior bilateral oophorectomy. 
P Pa at ti ie en nt ts s   a an nd d   m me et th ho od ds s: : Women with a BRCA1 or BRCA2 mutation with the diagnosis of invasive breast
cancer were identified from ten cancer genetics clinics. The medical history, medical treatment records and
pathology reports for the breast cancers were reviewed. Information was abstracted from medical charts,
including history (and date) of oophorectomy, date of breast cancer diagnosis, stage of disease, and
pathologic characteristics of the breast cancer. Women with prior bilateral oophorectomy were matched
by age, year of diagnosis, and mutation with one or more women who had two intact ovaries at the time
of breast cancer diagnosis. Characteristics of the breast tumours were compared between the two groups. 
R Re es su ul lt ts s: :   Women with prior bilateral oophorectomy presented with smaller tumours on average compared to women
without prior oophorectomy (mean size 1.50 cm vs. 1.95 cm; p=0.01). Additionally, although not statistically
significant, women with intact ovaries were more likely to have high-grade tumour (70% vs. 54%: p=0.10) and
to have positive lymph nodes (34% vs. 18%; p=0.11) compared to women with prior bilateral oophorectomy. 
C Co on nc cl lu us si io on ns s: :   Bilateral oophorectomy prior to breast cancer appears to favourably influence the biological
presentation of breast cancer in BRCA1 and BRCA2 mutation carriers. 
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I In nt tr ro od du uc ct ti io on n
Women with a BRCA1 or BRCA2 mutation have up
to an 87% lifetime risk of developing invasive breast
cancer [1]. The surgical removal of the ovaries in
women with a BRCA1 or BRCA2 mutation has been
shown to reduce the risk of developing breast cancer
[2]. Nevertheless, some women who have had bilateral
oophorectomy go on to develop breast cancer. Previous
research  has  suggested  that  there  may  be  an
association between menopausal status and prognostic
features of breast cancer [3], but this association has
not been studied in women with a BRCA1 or BRCA2
mutation. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 54
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Women with a BRCA1 or BRCA2 mutation are
encouraged to consider the option of prophylactic
oophorectomy to prevent both breast and ovarian
cancers. The recommended age for surgery is typically
prior to the age at which natural menopause would
occur.  In  our  recent  study  of  BRCA1  and  BRCA2
mutation carriers without cancer, 67% of women had
prophylactic oophorectomy to prevent breast and ovarian
cancer [4]. Bilateral oophorectomy reduces the risk of
developing breast cancer by up to 53% in BRCA1 and
BRCA2 mutation carriers [2]. It has also been shown that
ovarian ablation for the treatment of early breast cancer
significantly improves survival [5]. However, it is unknown
if prior bilateral oophorectomy reduces breast cancer
mortality in women with a BRCA1 or BRCA2 mutation.
If oophorectomy selectively prevents less aggressive
breast tumours, then the observed reduction in incidence
possibly may not be accompanied by parallel reduction
in mortality. It is therefore of interest to know whether
prior oophorectomy has any influence on the biological
presentation of breast cancer. We examined pathologic
features of invasive breast cancer in a series of women
with a BRCA1 or BRCA2 mutation and compared
features in women with and without prior bilateral
oophorectomy. 
M Me et th ho od ds s
S St tu ud dy y  s su ub bj je ec ct ts s
Pedigrees  of  cancer  families  followed  at  ten
participating cancer genetics clinics were reviewed.
A family was considered to be eligible for the study
when a BRCA1 or BRCA2 mutation was documented
in the family and at least one case of invasive breast
cancer was recorded. Eligible study subjects included
all women from these families who were diagnosed
with Stage I or Stage II breast cancer at the age of 65
or below, from 1975 to 2000. Living and deceased
women were eligible, but those with prior diagnosis of
cancer (including ovarian cancer) or those who resided
outside of North America were excluded. It was not
necessary that the woman was proven carrier of the
mutation found in the family to be included in the study;
however affected women who were known to be
non-carriers were excluded. 
We identified a total of 1139 breast cancer cases
in 337 families. Pedigree review indicated that 647 of
these were currently alive and that 492 were deceased.
Of the total of 1139 cases of breast cancer, 320
women were excluded because the date of diagnosis
was before 1975 and 50 women were excluded
because the age of diagnosis was above 65 years. An
additional 19 women were non-carriers of the familial
mutation and were therefore excluded. Ten women
were excluded because they had cancer (including
ovarian) diagnosed prior to breast cancer, and eleven
women were excluded because they were treated
outside of North America. 
We were able to obtain identifying information for
587 of the remaining 729 women (80.5%). An attempt
was made to contact each of these or her next of kin to
obtain permission to review the medical records. Thirteen
women (or their next of kin) refused to give their consent
to the release of the medical records. The medical record
was requested from the hospital where treatment was
received for the remaining 574 women. In 54 cases, the
hospital was not able to locate the record or did not
forward the requested documents. The medical record
was obtained on the remaining 520 women (91%). 
After review of the medical records an additional
29 women were excluded. Of these, 22 women were
excluded because the tumour was stage three or four;
six women were excluded because the tumour was non-
invasive (DCIS or LCIS); and one woman was excluded
because she refused treatment. The remaining 491
women were included in the analysis. 
S St tu ud dy y  p pr ro ot to oc co ol l  
The medical treatment records and pathology
documents  were  reviewed.  Information  that  was
abstracted from the medical charts included date of
breast cancer diagnosis, size of invasive tumour, nodal
status (number of nodes positive, number of nodes
examined), nuclear grade, ER (estrogen receptor) status,
PR (progesterone receptor) status, oophorectomy
(yes/no, date, indication), and current vital status
(living/deceased, cause of death). 
S St ta at ti is st ti ic ca al l  a an na al ly ys si is s
All data were analysed using the SAS software
program (version 8.2). Mean values of continuous
variables of cases and controls were compared by t-test
and frequencies of categorical variables were compared
by Chi-square test. In the comparison of variables, the
subjects with missing data were excluded. In the control
sets, if all the subjects had no data, it was listed as
missing data, or else the mean value of the control set
was used as the control mean for that case. 
R Re es su ul lt ts s
There were 491 women who were treated for stage
I or II breast cancer between 1975 and 2000. SixteenH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 55
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T Ta ab bl le e   1 1. .   Comparison of cases and controls
V Va ar ri ia ab bl le es s C Co on nt tr ro ol ls s   ( (n no o   b bi il la at te er ra al l   o oo op ph ho or re ec ct to om my y) )    C Ca as se es s   ( (h ha ad d   b bi il la at te er ra al l   o oo op ph ho or re ec ct to om my y) ) P P
( (2 27 7   s se et ts s, ,   1 13 38 8   s su ub bj je ec ct ts s) )    ( (N N= =2 27 7) )   
mean DOB 1943.8 1943.4 0.86*
mean age of diagnosis (range)  47.9 (35.7-63.3)  48.0 (36.0-63.2)  0.96*
mutation
BRCA1 74.1% 74.1%
BRCA2  25.9% 25.9%
ER-status (pos %)  33.6 40.0 0.62*
missing (n)  5 7
size (cm) (range)  1.95 (1.0-3.0) 1.50 (0.2-3.2) 0 0. .0 01 1* *
missing (n)  1 1
nodal status (% positive)  33.7 18.5 0.11*
* The data reported in the control column are mean of means of each set and were used in the tests. 
subjects had data missing on oophorectomy or date
of oophorectomy, and therefore were not included in
the analysis. An additional five women had a bilateral
oophorectomy within six months prior to breast cancer
diagnosis, and they were also excluded. Cases were
identified as those who had bilateral oophorectomy at
least six months prior to being diagnosed with invasive
breast  cancer.  There  were  28  women  who  were
identified as cases. These subjects were matched with
the remaining 442 control subjects by (1) date of birth
within five years; (2) breast cancer diagnosis within one
year; and (3) mutation (BRCA1 or BRCA2). There were
no controls found for one case, and therefore it was
excluded. For 27 cases at least one control was found,
resulting in a total of 138 controls. The ratio of case
to control was 1:4.8 (27:138). 
The mean age of breast cancer diagnosis for all of
the subjects (both cases and controls) was 47.9 years
(range 35.7-63.3 years). The mean time between
oophorectomy and breast cancer diagnosis for the
cases was 7.5 years (SD=6.8). 
Breast tumour characteristics (including ER status,
nuclear grade, size, and nodal status) of the cases and
controls were compared (Table 1). There was no
difference in ER status of the breast cancers for the
women who had bilateral oophorectomy compared to
those with intact ovaries (40.0% vs. 33.6% ER-positive;
p=0.62). There was a significant difference in the
tumour size between the two groups of subjects.
Women with prior bilateral oophorectomy presented
with smaller tumours on average compared to those
without oophorectomy (1.50 cm vs. 1.95 cm; p=0.01).
23.1% of women with prior oophorectomy had tumours
of 1 cm or less, compared to only 3.9% of women with
intact  ovaries  (OR=7.50;  p=0.04).  Additionally
(although not statistically significant) women with prior
oophorectomy were more likely to have a lower grade
tumour (grade I or II) (p=0.10) with negative lymph
nodes (p=0.11). Seventy percent of women with intact
ovaries presented with a poorly differentiated (grade
III) tumour compared to 54% of those with prior
bilateral oophorectomy (p=0.10). Additionally, women
with intact ovaries were almost twice as likely to present
with positive lymph nodes compared to women without
ovaries (33.7% vs. 18.5%; p=0.11). 
Tumour characteristics were also examined by gene
type (BRCA1 vs. BRCA2). BRCA2 carriers with prior
oophorectomy presented with lower grade tumours
than women with BRCA2 mutation with intact ovaries
(p=0.04). This was not observed in women with
a BRCA1 mutation (Table 2). The analyses were also
performed for ER status, size, and nodal status. No
differences between BRCA1 and BRCA2 mutation
carriers were observed (data not presented). 
Women were dichotomized by tumour characteristics
that were associated with a poor and good prognosis.
Women with a better prognosis were classified as those
with grade I or grade II tumour and tumour size of less
than or equal to 2 cm. All other subjects were assigned
to  the  group  that  had  less  favourable  tumour
characteristics. Women with prior oophorectomy were
twice as likely to have tumours that were classified as
having a better prognosis than women with intact
ovaries (OR= 0.50; 95%CI 0.17-1.47; p=0.21). 
D Di is sc cu us ss si io on n
This is the first study to examine the influence of
prior bilateral oophorectomy on the presentation ofH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 56
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invasive  breast  cancer  in  BRCA1  and  BRCA2
mutation carriers. 
We  matched  women  with  prior  bilateral
oophorectomy to those with intact ovaries in order to
compare the prognostic features of breast cancer.
Although the sample size was small, we observed that
women with prior bilateral oophorectomy were more
likely to be diagnosed with smaller, node negative, lower
grade tumours. There did not seem to be an influence
of  oophorectomy  on  ER  status,  suggesting  that
oophorectomy prevents ER-positive and ER-negative
tumours equally. Our results suggest that if breast cancer
develops after bilateral oophorectomy, the prognostic
features are likely to be more favourable than for those
women  with  intact  ovaries.  Therefore  bilateral
salpingo-oophorectomy prior to breast cancer is expected
to reduce mortality from breast cancer as well as
incidence [2, 6] in BRCA1 and BRCA2 mutation carriers. 
Tumour size has long been recognized as one of
the strongest predictors of outcome for patients with
invasive breast cancer [7-11]. Breast cancer lethality
increases with tumour size (although this has not yet
been shown in BRCA1 or BRCA2 mutation carriers).
We  found  that  prior  bilateral  oophorectomy  was
associated with a decreased size of breast tumour in
BRCA1 and BRCA2 mutation carriers. Twenty three
percent of women with oophorectomy presented with
tumours of 1 cm or less, compared to only four percent
of women with intact ovaries. However, we restricted
subjects to those with tumours of less than 5 cm, and
therefore this study group does not represent all tumours
that present in women with BRCA1 or BRCA2 tumours. 
BRCA1-associated breast cancers typically present
as high-grade tumours [12]. This does not seem to be
explained by early age of breast cancer onset in BRCA1
and BRCA2 mutation carriers [13]. When compared to
breast tumours from women of similar ages, BRCA1
and BRCA2 mutation carriers are shown to be more
likely to have higher overall grade tumours [13]. We
found that among women with a BRCA2 mutation,
those with prior oophorectomy presented with lower
grade tumours than those with intact ovaries. We did
not observe this effect with BRCA1 carriers. High grade
is an important index of poor prognosis [14, 15]. 
The presence of malignant disease in the regional
lymph nodes is another independent predictor of breast
cancer prognosis [9, 11, 16]. In our study group,
women with bilateral oophorectomy were more likely
to present with negative lymph nodes. In previous
studies, 42% of BRCA1 mutation carriers presented
with positive lymph nodes [17], and 37% of BRCA2
carriers presented with positive nodes [18]. These
frequencies are similar to what we observed in women
with intact ovaries in the present study (34%). However,
the proportion of women with positive lymph nodes
was lower in women without ovaries (18%). 
It is possible that women who had undergone
prophylactic oophorectomy may have been more
vigilant in undergoing screening. Breast cancers were
diagnosed between 1975 and 2000, therefore we
would not expect that many of the subjects would have
had access to MRI for breast screening and would have
relied on mammography. Our international database
of BRCA1 and BRCA2 mutation carriers indicates that
only 15% of all breast cancers were detected by
mammography; the great majority (74%) were detected
by breast self-examination (unpublished data). This
suggests that vigilant screening would not have affected
the results of this study greatly. However, if there was
an increase in screening, we may have observed
smaller tumours, but screening would not influence the
grade of the tumour. Our previous research has shown
that nodal status is not positively correlated with tumour
size  in  women  with  BRCA1  mutations  [19],  and
T Ta ab bl le e   2 2. .   Comparison of grade by mutation (BRCA1 and BRCA2) 
M Mu ut ta at ti io on n G Gr ra ad de e C Co on nt tr ro ol ls s    C Ca as se es s
( (n no o   b bi il la at te er ra al l   o oo op ph ho or re ec ct to om my y) )    ( (h ha ad d   b bi il la at te er ra al l   o oo op ph ho or re ec ct to om my y) ) P P
( (2 27 7   s se et ts s, ,   1 13 38 8   s su ub bj je ec ct ts s) )    ( (N N= =2 27 7) )
BRCA1  1 2 (2%) 2 (10.5%)
and BRCA2 2  28 (28%) 7 (36.8%) 0.10**
3 70 (70%) 10 (53.6%)
missing 38 8
BRCA1 1  2 (2.2%) 1 (6.7%) 
2  26 (28.3%) 4 (26.7%) 0.62
3 64 (69.5%) 10 (66.6%)
BRCA2 1  0 (0%) 1 (25.0%)
2  2 (25.0%) 3 (75.0%) 0 0. .0 04 4
3 6 (75.0%) 0 (0%)
** In this test the data in control were not the mean of set. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(2) 57
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therefore we would not expect that women with small
tumours would necessarily have negative lymph nodes. 
The  overall  evidence  for  the  importance  of
preventive  oophorectomy  for  BRCA1  and  BRCA2
mutation carriers is increasing. It has previously been
established that prophylactic oophorectomy in BRCA1
and BRCA2 mutation carriers prevents the development
of breast cancer [2, 6], prevents ovarian cancer [2], and
prevents the development of contralateral and ipsilateral
breast cancer after initial breast cancer [20]. Bilateral
oophorectomy may also offer a beneficial effect on the
prognostic factors of breast cancer that develops after
oophorectomy and it is expected that survival rates in
oophorectomized women will also be higher than those
of women who choose to retain their ovaries. 
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